Screener
Jazz Pharmaceuticals JAZZ Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred tax assets, net | 907.0 | 869.1 |
| Deferred financing costs | 7.1 | 7.6 |
| Other non-current assets | 94.7 | 99.0 |
| Total assets | $11,859.6 | $11,659.3 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $100.0 | $122.1 |
| Accrued liabilities | 1,022.4 | 1,034.2 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's total assets?
- Jazz Pharmaceuticals (JAZZ) reported total assets of $11.86B in Q1 2026.
- How has Jazz Pharmaceuticals's total assets changed year-over-year?
- Jazz Pharmaceuticals's total assets increased by 2.8% year-over-year, from $11.53B to $11.86B.
- What is the long-term trend for Jazz Pharmaceuticals's total assets?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total assets has grown at a 12.3% compound annual growth rate (CAGR), from $6.54B to $11.66B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Jazz Pharmaceuticals's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude